Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction

EuroIntervention

Volumn 8, Issue 1, 2012, Pages 71-78

  Vranckx, Pascal ^a   Campo, Gianluca ^b,c   Anselmi, Maurizio ^d   Bolognese, Leonardo ^e   Colangelo, Salvatore ^f   Biondi Zoccai, Giuseppe ^g   Moreno, Raul ^h   Piva, Tommaso ⁱ   Favero, Luca ^j   Prati, Francesco ^k   Nazzaro, Marco ^l   Díaz Fernández, José F ^m   Ferrari, Roberto ^b,c   Valgimigli, Marco ^b,c  

^a Hartcentrum   (Belgium)

^b UNIVERSITY OF FERRARA   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e IRCCS POLICLINICO SAN DONATO   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ Azienda Ospedaliera Umberto I   (Italy)

^j Civic Hospital   (Italy)

^k CATHOLIC UNIVERSITY   (Italy)

^l SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^m HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

more..

Author keywords

Access site; Acute myocardial infarction; Haemorrhage; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; RAPAMYCIN; TIROFIBAN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CAUSE OF DEATH; CORONARY STENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; RECURRENT DISEASE; RETROPERITONEAL HEMORRHAGE; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURGICAL RISK; UROGENITAL TRACT DISEASE; VASCULAR ACCESS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ARGENTINA; BLOOD TRANSFUSION; CHI-SQUARE DISTRIBUTION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PUNCTURES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPAIN; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865467598     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I1A12     Document Type: Article

References (29)

1. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM; Topol EJ. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759-1765.
2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society.ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82-e292. (Erratum, Circulation. 2005;111:2013-4; 2007;115:e411; 2010 ;121:e441.)
3. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296-329. (Erratum, Circulation. 2008;117:e162.)
4. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO; 2005 WRITING COMMITTEE MEMBERS, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261-295. (Erratum, Circulation. 2008;117:e161.)
5. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction: ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734-741.
6. Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G. Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial. Circulation. 2008;118:49-57.
7. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. European Heart Journal. 2009;30:2705-2713.
8. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). European Heart Journal. 2003;24: 1815-1823.
9. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114: 774-782.
10. Serruys PW, Daemen J, Morice MC, De Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Dawkins KD, Vranckx P, Bressers M, van Domburg R, Schuijer M, Wittebols K, Pieters M, Stoll HP. Three year Follow-up of the ARTSII-Sirolimus eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention. 2008;4:450-459.
11. Cohen M. Predictors of bleeding risk and long-term mortality in patients with acute coronary syndromes. Curr Med Res Opin. 2005;21:439-445.
12. Valgimigli M, Bolognese L, Anselmi M, Campo G, Rodriguez AE, de Cesare N, Cohen DJ, Sheiban I, Colangelo S, Pasquetto G, Hamon M, Vranckx P, Ferrario M, Prati F, Agostoni P, Malagutti P, Arcozzi C, Parrinello G, Vassanelli C, Ferrari R, Percoco G. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial. Am Heart J. 2007;154:39-45.
13. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R. Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction. The MULTISTRATEGY Randomized Trial. JAMA. 2008;299:1788-1799.
14. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, Moliterno DJ, Lincoff AM, Amstrong PW, Van de Werf F, Califf RM, Harrington RA. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:809-16.
15. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216.
16. Landefeld LS, Cook EF, Hatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1987;82:703-713.
17. Van't Hof AWJ, ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JE, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372:537-546.
18. Mehran R, Lansky AJ, Witzenbichler B; HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374: 1149-1159.
19. White HD, Aylward PE, Gallo R, Bode C, Steg G, Steinhubl SR, Montalescot G. STEEPLE Investigators. Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. Am Heart J. 2010;159:110-6.
20. Doyle BJ, Ting HH, Bell MR, Lennon RJ, Verghese M, Singh M, Holmes DR, Rihal CS. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. J Am Coll Cardiol Intv. 2008;1:202-209.
21. Agostoni P, Biondi-Zoccai GG, de Benedictis ML, Biondi- Zoccai GGL, Rigattieri S, Turri M, Anselmi M, Vassanelli C, Zardini P, Louvard Y, Hamon M. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004;44:349-356.
22. Cayla G, Silvain J, Barthelemy O, Connor S, Payot L, Bellemain-Appaix A, Beygui F, Aout M, Collet JP, Vicaut E, Montalescot G; ABOARD investigators. Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. Heart. 2011;97:887-891.
23. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233-1243.
24. Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, Mehran R. Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications. Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. J Am Coll Cardiol. 2009;54: 1293-1302.
25. Batth DL. Cogent: a prospective, randomized, placebo controlled trial of omeprazole in patients receiving asprin and clopidogrel. Late breaking clinical trials presentation. TCT2009, September, San Francisco.
26. Spencer FA, Moscucci M, Granger CB. Dies comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007;116: 2793-801.
27. Jolicœur EM, O'Neill WW, Hellkamp A, Hamm CW, Holmes DR Jr, Al-Khalidi HR , Patel MR, van de Werf FJ, Pieper K, Armstrong PW, Granger CB; APEX-AMI Investigators. Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. European Heart Journal. 2009;30:2575-2583.
28. Verheugt FWA, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Incidence, prognostic impact, and influence of antithrombotic therapy on access and non access site bleeding in percutaneous coronary intervention. J Am Coll Cardiol Intv. 2011;4:191-7.
29. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556-2566.